Exelixis Inc. [NASDAQ: EXEL] loss -0.60% or -0.1 points to close at $16.69 with a heavy trading volume of 2900472 shares. The company report on January 8, 2023 that Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023.
– Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 –.
– Full year 2023 net product revenues guidance of $1,575 million – $1,675 million –.
It opened the trading session at $16.71, the shares rose to $16.715 and dropped to $16.40, the range by which the price of stock traded the whole day. The daily chart for EXEL points out that the company has recorded -21.83% loss over the past six months. However, it is still -12.24% lower than its most recent low trading price.
If we look at the average trading volume of 2.20M shares, EXEL reached to a volume of 2900472 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Exelixis Inc. [EXEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXEL shares is $25.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JMP Securities have made an estimate for Exelixis Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on October 18, 2022. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on June 24, 2022, representing the official price target for Exelixis Inc. stock. Previously, the target price had yet another raise to $34, while Piper Sandler analysts kept a Overweight rating on EXEL stock.
The Average True Range (ATR) for Exelixis Inc. is set at 0.52, with the Price to Sales ratio for EXEL stock in the period of the last 12 months amounting to 3.16. The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 4.99. Price to Free Cash Flow for EXEL in the course of the last twelve months was 15.06 with Quick ratio for the last quarter at 6.00.
Trading performance analysis for EXEL stock
Exelixis Inc. [EXEL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.60. With this latest performance, EXEL shares gained by 3.79% in over the last four-week period, additionally sinking by -21.83% over the last 6 months – not to mention a drop of -8.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXEL stock in for the last two-week period is set at 53.17, with the RSI for the last a single of trading hit 53.69, and the three-weeks RSI is set at 52.15 for Exelixis Inc. [EXEL]. The present Moving Average for the last 50 days of trading for this stock 16.49, while it was recorded at 16.95 for the last single week of trading, and 18.72 for the last 200 days.
Exelixis Inc. [EXEL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Exelixis Inc. [EXEL] shares currently have an operating margin of +19.98 and a Gross Margin at +96.32. Exelixis Inc.’s Net Margin is presently recorded at +16.10.
Return on Equity for this stock inclined to 11.30, with Return on Assets sitting at 9.70.
Exelixis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.10.
Exelixis Inc. [EXEL]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EXEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Exelixis Inc. go to 46.00%.
An analysis of insider ownership at Exelixis Inc. [EXEL]
There are presently around $4,575 million, or 88.10% of EXEL stock, in the hands of institutional investors. The top three institutional holders of EXEL stocks are: BLACKROCK INC. with ownership of 33,895,320, which is approximately 1.009% of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 31,284,832 shares of the stock with an approximate value of $522.14 million in EXEL stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $267.56 million in EXEL stock with ownership of nearly -9.858% of the company’s market capitalization.
Positions in Exelixis Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 225 institutional holders increased their position in Exelixis Inc. [NASDAQ:EXEL] by around 24,750,012 shares. Additionally, 158 investors decreased positions by around 23,596,898 shares, while 55 investors held positions by with 225,748,643 shares. The mentioned changes placed institutional holdings at 274,095,553 shares, according to the latest SEC report filing. EXEL stock had 69 new institutional investments in for a total of 11,530,432 shares, while 38 institutional investors sold positions of 1,666,468 shares during the same period.